The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Ropinirole for the treatment of early Parkinson's disease
Abstract
A prospective, randomized, placebo-controlled, double-blind, parallel-group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn & Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Packer, M., Gheorghiade, M., Young, J. B., Costantini, P. J., Adams, K. F., Cody, R. J., Smith, L. K., Van Voorhees, L., Gourley, L. A., & Jolly, M. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307013290101 · Cited by 827
(1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292417 · Cited by 639
Physical therapy and Parkinson's disease: A controlled clinical trial
Comelia, C. L., Stebbins, G. T., Brown-Toms, N., & Goetz, C. G. (1994) · Neurology · doi:10.1212/wnl.44.3_part_1.376 · Cited by 236
Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., et al. (1994) · Movement Disorders · doi:10.1002/mds.870090107 · Cited by 204
The rationale for the use of dopamine agonists in Parkinson's disease
Jenner, P. G. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s6 · Cited by 149
Weiner, W. J., Factor, S. A., Sanchez‐Ramos, J., Singer, C., Sheldon, C., Cornelius, L., & Ingenito, A. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.21 · Cited by 137
Self-citationShould Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment
Fahn, S., & Bressman, S. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046412 · Cited by 101
Dopamine agonists in Parkinson's disease
Wolters, E. C., Tissingh, G., Bergmans, P., & Kuiper, M. A. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s28 · Cited by 60
Diabetic Neuropathy: Models, Mechanisms and Mayhem
Thomas, P. K. (1992) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100042463 · Cited by 57
Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases
Ho, K. K. Y., & Thorner, M. O. (1988) · Drugs · doi:10.2165/00003495-198836010-00005 · Cited by 52
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationAn algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., & Fahn, S. (1999) · Neurology · doi:10.1212/wnl.52.9.1908 · Cited by 692
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Deleu, D., Northway, M. G., & Hanssens, Y. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00003 · Cited by 349
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Limitations of current Parkinson's disease therapy
Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel-Courbon, C., & Montastruc, J.-L. (2003) · Annals of Neurology · doi:10.1002/ana.10513 · Cited by 337
Minimal clinically important change on the unified Parkinson's disease rating scale
Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006) · Movement Disorders · doi:10.1002/mds.20914 · Cited by 297
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease
Pahwa, R., Stacy, M. A., Factor, S. A., Lyons, K. E., Stocchi, F., Hersh, B. P., Elmer, L. W., Truong, D. D., & Earl, N. L. (2007) · Neurology · doi:10.1212/01.wnl.0000258660.74391.c1 · Cited by 290
Treatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C., Koller, W., Poewe, W., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., et al. (2008) · Movement Disorders · doi:10.1002/mds.21894 · Cited by 253
Self-citation
Metadata
- Authors
- Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group
- Venue
- Neurology
- Published
- 1997-08
- Volume
- 49
- Issue
- 2
- Pages
- 393-399
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2169741346
- Cited by
- 281
- References
- 14
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.